Xiaoling Xu1, Liuhong Shi2, Xiuqing Ma1, Hua Su1, Guofeng Ma1, Xiaohong Wu1, Kejing Ying1, Ruifeng Zhang3. 1. Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China. 2. Department of Ultrasound, the Second Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China. 3. Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China. Electronic address: zhangruifeng@zju.edu.cn.
Abstract
INTRODUCTION: Acute pulmonary embolism (APE) is a cardiovascular disease with high morbidity and mortality. Although the anatomical obstruction of the pulmonary vascular bed initiates APE, recent studies have suggested that vasoconstrictors in the renin-angiotensin system (RAS) play a role in the severity of APE. MATERIALS AND METHODS: We performed a 5-year retrospective clinical study to analyze the key RAS components in APE patients, including angiotensin converting enzyme (ACE), ACE2, angiotensin II (Ang II) and angiotensin 1-7(Ang(1-7)). The role of RhoA-Rho associated kinase (ROCK) signaling in regulating RAS vasoconstrictors was detected in rat pulmonary artery endothelial cells and in an APE rat model. RESULTS: In clinical study, we found that the levels of RAS vasoconstrictors were correlated with the clinical classification of APE patients, ACE and Ang II were unregulated, whereas ACE2 and Ang(1-7) were downregulated in the high-risk group compared to the healthy volunteers. In animal study, we found that activated RhoA-ROCK signaling was responsible for the imbalance in RAS vasoconstrictors both in vitro and in vivo, and further evidence indicated that ROCK inhibitors (Y27632 or HA1077) and an ACE2 activator (Resorcinol naphthalein) restored the dysregulated RAS vasoconstrictors significantly and had a protective role in an APE rat model. CONCLUSIONS: Our study revealed that RhoA-ROCK signaling leads to RAS imbalance in APE patients, and ACE2 activation might be a novel therapeutic target in APE treatment.
INTRODUCTION: Acute pulmonary embolism (APE) is a cardiovascular disease with high morbidity and mortality. Although the anatomical obstruction of the pulmonary vascular bed initiates APE, recent studies have suggested that vasoconstrictors in the renin-angiotensin system (RAS) play a role in the severity of APE. MATERIALS AND METHODS: We performed a 5-year retrospective clinical study to analyze the key RAS components in APE patients, including angiotensin converting enzyme (ACE), ACE2, angiotensin II (Ang II) and angiotensin 1-7(Ang(1-7)). The role of RhoA-Rho associated kinase (ROCK) signaling in regulating RAS vasoconstrictors was detected in rat pulmonary artery endothelial cells and in an APE rat model. RESULTS: In clinical study, we found that the levels of RAS vasoconstrictors were correlated with the clinical classification of APE patients, ACE and Ang II were unregulated, whereas ACE2 and Ang(1-7) were downregulated in the high-risk group compared to the healthy volunteers. In animal study, we found that activated RhoA-ROCK signaling was responsible for the imbalance in RAS vasoconstrictors both in vitro and in vivo, and further evidence indicated that ROCK inhibitors (Y27632 or HA1077) and an ACE2 activator (Resorcinol naphthalein) restored the dysregulated RAS vasoconstrictors significantly and had a protective role in an APE rat model. CONCLUSIONS: Our study revealed that RhoA-ROCK signaling leads to RAS imbalance in APE patients, and ACE2 activation might be a novel therapeutic target in APE treatment.
Authors: Soudeh Ghafouri-Fard; Rezvan Noroozi; Mir Davood Omrani; Wojciech Branicki; Ewelina Pośpiech; Arezou Sayad; Krzysztof Pyrc; Paweł P Łabaj; Reza Vafaee; Mohammad Taheri; Marek Sanak Journal: Vascul Pharmacol Date: 2020-05-11 Impact factor: 5.773
Authors: Maria Paz Ocaranza; Jaime A Riquelme; Lorena García; Jorge E Jalil; Mario Chiong; Robson A S Santos; Sergio Lavandero Journal: Nat Rev Cardiol Date: 2019-08-19 Impact factor: 32.419
Authors: Radu Crisan-Dabija; Cristina Alice Pavel; Iolanda Valentina Popa; Andrei Tarus; Alexandru Burlacu Journal: J Proteome Res Date: 2020-09-17 Impact factor: 4.466
Authors: Teresa Segura de la Cal; Jorge Nuche; Carmen Jiménez López-Guarch; Carmen Pérez-Olivares; Maite Velázquez; Francisco López-Medrano; María Jesús López Gude; Sergio Alonso Charterina; Fernando Arribas Ynsaurriaga; Pilar Escribano Subías Journal: Arch Bronconeumol (Engl Ed) Date: 2020-06-26 Impact factor: 4.872